Canine CAR-T Engineering Service

Creative Biolabs specializes in offering canine CAR-T engineering services to speed up global clients' projects.

The Rational of Canine CART

Canine serves as an excellent model for human disease. There are over 300 diseases that have been described as similar to human disease, including several cancers such as leukemia, lymphoma, osteosarcoma, and melanoma. Moreover, canine tumors occur spontaneously, which recapitulates the natural development process of tumors and the multi-directional tumor environment. With the further development of CAR-T research, it is more important to find suitable animal models. The development of canine CAR-T will help further promote CAR-T research for human disease.

Fig.1 Companion animals and humans share very similar living environments and exposures.¹

One Stop Canine CAR-T Engineering Service

With years of experience in CAR-T research, Creative Biolabs provides one-stop canine CAR-T engineering services to help accelerate scientific research for global customers.

Fig.2 Overall scheme for canine CAR therapy. (Cockey & Leifer, 2023)

• Comprehensive CAR Design and Construction Strategies to Assist Canine CAR-T Engineering

The classic CAR design strategies from 1^st to 5^th generation provide high specificity and effectiveness for redirecting T cells to target cancer cells. At the same time, Creative Biolabs offers a variety of special CAR designs according to clients' needs.

Fig.3 Classic CAR design strategies. (Miao, et al., 2021)

• Outstanding CAR-T Gene Packaging & Delivery Solutions to Enable Canine CAR-T Engineering

Since the T cells are difficult to modify, the electroporation transfection and transposon transfection systems are more robust to complete the T-cell transfection. Creative Biolabs provides various transfection technology with strict quality control to speed up the Canine CAR-T Engineering.

Features & Benefits

Creative Biolabs is confident in providing one-stop canine CAR-T engineering services with mature experience and expertise.

Published Data

• Paper Title: Establishing a model system for evaluating CAR-T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
• Summary: The researchers designed and produced anti-canine CD20, 2^nd generation canine CAR-T cells for in vitro and in vivo functional assessment using lentiviral vectors in parallel with human CAR-T cell production. This canine CD20 CAR-T system showed promising results in the treatment of canine diffuse large B cell lymphoma (DLBCL).
• Technology: Lentivectors transfection
• CAR Construction Generation: 2^nd generation
• Cell Type: Canine T cells
• Results:

We offer professional guidance for canine CAR-T engineering projects, please contact us for a tailored solution for you.

References

1. Oh, Ji Hoon, and Je-Yoel Cho. "Comparative oncology: overcoming human cancer through companion animal studies." Experimental & Molecular Medicine 55.4 (2023): 725-734.
2. Cockey, James R., and Cynthia A. Leifer. "Racing CARs to veterinary immuno-oncology." Frontiers in Veterinary Science 10 (2023): 1130182.
3. Miao, Lele, et al. "Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors." Frontiers in Immunology 12 (2021): 687822.